Navigation Links
Janssen Neuroscientists and Colleagues Challenge Healthcare Industry to Create Integrated Approaches to Healthcare Innovation in Newly Published Article
Date:2/5/2013

TITUSVILLE, N.J., Feb. 5, 2013 /PRNewswire/ -- Janssen Research & Development, LLC, ("Janssen") announced today the publication of a new article that addresses integrated approaches to healthcare solutions. The authors challenge the healthcare industry to expand its thinking beyond product-focused, "magic bullet" drug development and discuss the need for an integrated approach to patient care, including use of devices, tools and services to help a patient's progress. The commentary, "Beyond magic bullets: true innovation in health care," was published in the February 2013 issue of Nature Reviews Drug Discovery and is available at: http://www.nature.com/nrd/journal/v12/n2/full/nrd3944.html.

"We are in the middle of a revolution for molecular medicine. Advances in the field are constantly yielding new information about the body and its diseases. The need to differentiate from existing therapies and the mandate for innovation are clear," said Husseini K. Manji , M.D., Global Therapeutic Area Head for Neuroscience, Janssen Research & Development, LLC, and senior author of the article. "Scientists and business leaders are looking for and implementing new strategies to bring forth innovative therapeutic approaches that are meaningful and measurable to patients, caregivers and payers."

The authors discuss solutions for central nervous system (CNS) disorders – a group of diseases and illnesses identified as one of the biggest challenges to our healthcare and economic environment. The predicted cost of these disorders to society worldwide is higher than that of cancer, diabetes and chronic respiratory diseases combined,[1] and many serious mental illnesses, for example, can affect a patient's ability to take medicines on a regular basis and become engaged in a treatment plan. The authors sugge
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
11. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... pre-clinical study published in the Proceedings of ... ) that showed when ibrutinib (IMBRUVICA ® ) ... inhibitor), suppression of tumor growth was enhanced suggesting ... certain hematologic cancers and solid tumors with the ...
(Date:2/27/2015)... 27, 2015  Following a bipartisan vote in ... H.R. 284, the Medicare DMEPOS Competitive Bidding Improvement ... Homecare (AAHomecare) released a statement praising the Committee,s ... the legislation. "Today,s mark-up of the ... and Means Committee is a critical step forward ...
(Date:2/27/2015)... 27, 2015 Securities lawyers at Dunnam ... Pharmaceuticals, Ltd. (NASDAQ: SLXP ) in connection ... SLXP investors are encouraged to contact attorney Hamilton Lindley ... investigation focuses upon the shareholder value of the transaction. ... receive only $158.00 per share in cash. At least ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2
... ... demonstrated to be safe and well-tolerated in Phase I - - Presentation of ... call today at 5:00 p.m. ... Eastern Time -, BRANFORD, Conn., Oct. 25 CuraGen Corporation,(Nasdaq: ...
... 25 ,Today Bayer announced new guidance to physicians ... (aprotinin injection) in patients at an,increased risk of ... graft (CABG) surgery with cardiopulmonary bypass (CPB). ... the BART Executive,Committee had halted the Canadian-based trial ...
Cached Medicine Technology:CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 2CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 3CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 4CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 5CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 6CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 7CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 8CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference 9Bayer Issues Additional Guidance to Physicians on Trasylol(R) 2Bayer Issues Additional Guidance to Physicians on Trasylol(R) 3Bayer Issues Additional Guidance to Physicians on Trasylol(R) 4Bayer Issues Additional Guidance to Physicians on Trasylol(R) 5
(Date:3/1/2015)... 2015 Researchers say working around asbestos-containing ... sheet metal workers contract malignant mesothelioma. Surviving Mesothelioma has ... its website. Click here to read it now. ... and Training monitored 17,345 sheet metal workers from 1986 ... them died of mesothelioma or another asbestos-related disease ...
(Date:3/1/2015)... (PRWEB) March 01, 2015 ERISAPros ... King and Carolyn Roddy to the professional staff of ... Compliance, graduated from The Ohio State University-Mortiz College of ... years of experience working with several Fortune 500 companies ... the area of corporate benefits. Her experiences range from ...
(Date:2/28/2015)... In recent years Medical Marijuana has continuously ... as a way for them to expand their patient base ... medicine. Since the FDA still lists Cannabis as a Schedule ... licensed physicians that can help guide them when recommending ... in Santa Cruz, CA is a leader in the ...
(Date:2/28/2015)... 2015 The Heart Fit Clinic started ... of the machine. The Heart Fit Clinic is also ... a franchise model. The goal is to scale the ... disease. To buy External Counterpulsation machines can ... individuals through this process and achieve the desired results. ...
(Date:2/28/2015)... Indosoft Inc , developers of ... are pleased to announce the development of Q-Suite 5.9. ... versions of Q-Suite, this new version will include enhancements ... new features to the leading edge call center software. ... will add features to enhance security and protection. Administrators ...
Breaking Medicine News(10 mins):Health News:New Study Finds Indirect Asbestos Exposure Can Raise Mesothelioma Risk for Sheet Metal Workers, According to Surviving Mesothelioma 2Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2
... immune system, says a study conducted by Spanish researchers . ... C, B-complex vitamins and has good doses of minerals like ... known that potatoes are good for bowel health. ... particularly if eaten cold or in a salad, the researchers ...
... to the coastal Spanish town of Altea to get Oslo-funded ... to fractured bones. ,"In Norway it is cold ... why they are better off here," the tanned head of ... ,The rehabilitation centre was set up and is run by ...
... are an indicator of an industry's health, then the turnout ... and spirits fair, confirms the sector is doing nicely, if ... this year's show, a two-yearly event in Bordeaux, a three ... for Vinexpo by the London-based International Wine and Spirit Record ...
... with a life-threatening illness, a young Indian American is hard ... 10 as very few South Asians are listed in the ... Chakravarthy was diagnosed with a disease known as Acute Myelogenous ... bone marrow, the South Asian community has come together nationwide ...
... up with a partner in Harley Street - a ... are frequented by celebrities - and is introducing ... into tie-up based on her franchise system with the ... Ayurveda on Harley Street is indicative of the increasing ...
... Fey has launched an entirely new kind of healthcare ... culture of prevention throughout America and the world -- ... to one that encourages people to take early steps ... ,This message appears this week in a full-page ad in ...
Cached Medicine News:Health News:Intake of Potatoes Boosts the Immune System 2Health News:Norwegians Take in the Sun in Spain on Doctors' Orders 2Health News:World Wine Sales Brisk, but French Producers Hungover 2Health News:World Wine Sales Brisk, but French Producers Hungover 3Health News:South Asians Seek Bone Marrow for Young Indian American 2Health News:Shahnaz Hussain Takes Ayurveda to London's Harley Street 2Health News:U.S. Preventive Medicine(R) Encourages the International Community to Embrace Prevention 2
... stabilizer from Guidant. , Designed ... The newest members of the ACROBAT family ... outstanding anastomotic site visibility and access. Featuring ... technology on a stronger arm, our innovative ...
... 5 system is an intuitive, all-in-one ... to minimize the scarring and risk ... procedures. Incorporating an enhanced, ergonomic handle ... operative obstructions, this new device is ...
... The AB-180 iVAD*, implantable ... a surgically implantable device ... The inflow and outflow ... the VAD and anatomically ...
The MicroMed DeBakey VAD is a miniaturized heart pump designed to provide increased blood flow (up to 10L/min) from the left ventricle of the heart throughout the body for patients in end stage heart...
Medicine Products: